Publications

5596 Results

Time to target TIM-3 in colorectal cancer: TIM-3 expression to predict survival outcomes in patients in CALGB (Alliance)/SWOG 80405

Authors
S Algaze;Y Yang;J Millstein;F Battaglin;S Soni;P Mittal;K Ashouri;P Jayachandran;H Arai;J Ho Lo;W Zhang;L Torres-Gonzalez;A Wong;H-J Lenz
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster; J Clin Oncol 42, 2024 (suppl 16; abstr 3583)
Year
2024
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC)

Authors
C Rocha Lima;G Yothers;Puhalla;H Sanoff;D Cohen;K Guthrie;N Henry;P Ganz;S Kopetz;P Lucas;C Blanke;S Jacobs;T Hong;N Wolmark;H Hochster;T George;M Overman
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), TIP poster; J Clin Oncol 42, 2024 (suppl 16; abstr TPS3632)
Year
2024
Research Committee(s)
Gastrointestinal

A Randomized Phase II trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma (SWOG S1701)

Authors
A Tsao;M Hsieh;M Koczywas;J Tu;J Riess;T Tanvetyanon;B Ma;Y Zhao;M Redman;M Edelman;D Gandara;K Kelly;J Gray
Journal / Conference
ASCO Annual Meeting (May/31-June 4, 2024, Chicago, IL), poster; J Clin Oncol 42, 2024 (suppl 16; abstr 8110)
Year
2024
Research Committee(s)
Lung
Study Number(s)
S1701

Multi-stakeholder, intentional outreach for improving representative recruitment in Pragmatica–Lung (SWOG S2302)

Authors
D Carrizosa;J Miao;K Reckamp;K Dragnev;P Hesketh;W Iams;B Henick;C Czerlanis;F DeSanto;J Sundstrom;J Johnson;L Gansauer;T Groller;M Redman;R Herbst;J Gray
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster; J Clin Oncol 42, 2024 (suppl 16; abstr 11019)
Year
2024
Research Committee(s)
Lung
Study Number(s)
S2302

Correlations Between First Cycle Toxicity and Overall Survival in Patients with Rare Cancers Treated with Immune Checkpoint Inhibitors (NCI/SWOG S1609)

Authors
M Othus;S Patel;YK Chae;E Dietrich;H Streicher;E Sharon;R Kurzrock
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster;J Clin Oncol 42, 2024 (suppl 16; abstr 2655)
Year
2024
Research Committee(s)
Early Therapeutics and Rare Cancers
Study Number(s)
S1609

Correlation of Body Mass Index (BMI) with survival outcomes in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Analysis of Patient (pt) Level Data from SWOG 1216 study

Authors
U Swami;Y Jo;A Narang;M Plets;C Chehade;G Gebrael;S Gupta;Z Myint;C Tangen;P Lara;I Thompson;M Hussain;T Dorff;S Lerner;N Agarwal
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster;J Clin Oncol 42, 2024 (suppl 16; abstr 5081)
Year
2024
Research Committee(s)
Genitourinary
Study Number(s)
S1216

SWOG S2302, PRAGMATICA - LUNG: A Prospective Randomized Study of Ramucirumab plus Pembrolizumab (PR) versus Standard of Care (SOC) for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer

Authors
K Reckamp;M Redman;K Dragnev;W Iams;B Henick;J Miao;D Carrizosa;RS Herbst;J Gray
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), TIP, poster; J Clin Oncol 42, 2024 (suppl 16; abstr TPS8657)
Year
2024
Research Committee(s)
Lung
Study Number(s)
S2302

SWOG S2012: Randomized Phase II/III Trial of First Line Platinum (P) / Etoposide (E) with or without Atezolizumab (NSC #783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)

Authors
D Zhen;A Moseley;EG Chiorean;E Burgess;E Swisher;C Gay;L Byers;I Wistuba;H Mahdi;J Starr;M Othus;Y Chae;R Kurzrock
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), TIPS, poster; J Clin Oncol 42, 2024 (suppl 16; abstr TPS4201)
Year
2024
Research Committee(s)
Early Therapeutics and Rare Cancers
Study Number(s)
S2012

A phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937- Updated Design

Authors
S Sadeghi;M Plets;P Lara;C Tangen;S Berg;J Brown;R Bangs;D Nakagawa;S Daneshmand;I Thompson;T Flaig;D Petrylak;S Lerner
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster; J Clin Oncol 42, 2024 (suppl 16; abstr TPS4617)
Year
2024
Research Committee(s)
Genitourinary
Study Number(s)
S1937

Association between Postoperative Circulating Tumor DNA (ctDNA) and Recurrence-Free Survival (RFS) in Patients with Resected Stage III Melanoma - an Exploratory Analysis of SWOG S1404

Authors
M LaPelusa;D Marcano;M Othus;A Grossmann;V Aushev;B Sridhar;D Renner;H Sethi;M Liu;A Tarhini;J Kirkwood;K Grossmann;J Moon;H Li;S Mashrun;N Khushalani;E Sharon;L Korde;A Ribas;S Patel
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster; J Clin Oncol 42, 2024 (suppl 16; abstr 9564)
Year
2024
Research Committee(s)
Melanoma
Study Number(s)
S1404